Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 10,000 shares of the firm’s stock in a transaction on Tuesday, June 8th. The shares were sold at an average price of $70.18, for a total transaction of $701,800.00. Following the completion of the transaction, the insider now directly owns 523,904 shares of the company’s stock, valued at approximately $36,767,582.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Derek J. Maetzold also recently made the following trade(s):
- On Monday, April 26th, Derek J. Maetzold sold 14,374 shares of Castle Biosciences stock. The shares were sold at an average price of $69.17, for a total transaction of $994,249.58.
NASDAQ CSTL opened at $71.22 on Friday. The business’s 50-day moving average is $63.70. The firm has a market cap of $1.78 billion, a PE ratio of -100.31 and a beta of 0.42. Castle Biosciences, Inc. has a 52-week low of $34.72 and a 52-week high of $107.69.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Principal Financial Group Inc. lifted its stake in shares of Castle Biosciences by 13.0% during the 1st quarter. Principal Financial Group Inc. now owns 88,564 shares of the company’s stock worth $6,063,000 after buying an additional 10,212 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new stake in shares of Castle Biosciences during the 1st quarter worth about $300,000. Voloridge Investment Management LLC lifted its stake in shares of Castle Biosciences by 16.1% during the 1st quarter. Voloridge Investment Management LLC now owns 41,070 shares of the company’s stock worth $2,812,000 after buying an additional 5,692 shares during the last quarter. Grandeur Peak Global Advisors LLC lifted its stake in shares of Castle Biosciences by 346.1% during the 1st quarter. Grandeur Peak Global Advisors LLC now owns 39,339 shares of the company’s stock worth $2,693,000 after buying an additional 30,520 shares during the last quarter. Finally, Select Equity Group L.P. acquired a new stake in shares of Castle Biosciences during the 1st quarter worth about $24,651,000. Institutional investors own 84.99% of the company’s stock.
A number of research analysts recently weighed in on CSTL shares. Lake Street Capital started coverage on shares of Castle Biosciences in a research report on Friday, April 30th. They issued a “buy” rating and a $94.00 target price for the company. Zacks Investment Research upgraded shares of Castle Biosciences from a “sell” rating to a “hold” rating in a research note on Monday, May 10th. Finally, Robert W. Baird reiterated a “buy” rating and issued a $73.00 price target on shares of Castle Biosciences in a research note on Thursday, May 13th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $80.29.
About Castle Biosciences
Castle Biosciences, Inc, a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue.
Recommended Story: What is the outlook for the FAANG stocks?
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.